Aprepitant CAS NO.170729-80-3

Aprepitant CAS170729-80-3, purity at least 99.6% Product name AprepitantSynonyms 5-[2(R)-[1(R)-[3, 5-Bis (trifluoromethyl) phenyl] e…

Aprepitant CAS170729-80-3, purity at least 99.6% Product name AprepitantSynonyms 5-[2(R)-[1(R)-[3, 5-Bis (trifluoromethyl) phenyl] ethoxy] - 3(S)-(4-fluorophenyl) morpholin-4-ylmethyl]-3, 4-dihydro- 2H-1, 2, 4-triazol-3-oneCAS No. 170729-80-3Molecular weight 534.43Molecular formula C23H21F7N4O3Useanti-nausea Appearancewhite powder  General introductionAprepitant is for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003. Aprepitant may also be useful in the treatment of cyclic vomiting syndrome but there are few studies to date.   Mechanism of actionAprepitant is classified as an NK1 antagonist which is because it blocks signals given off by NK1 receptors. This therefore decreases the likelihood of a patient experiencing nausea vomiting. Emend is usually taken as a preventative for CINV, which is a serious side effect experienced by over 80% of patients who undergo chemotherapy.